Northern Trust Corp Raises Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Northern Trust Corp raised its stake in shares of Amedisys, Inc. (NASDAQ:AMED) by 23.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 289,228 shares of the health services provider’s stock after purchasing an additional 55,264 shares during the quarter. Northern Trust Corp owned approximately 0.88% of Amedisys worth $26,259,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in AMED. Barclays PLC increased its position in Amedisys by 49.5% during the 3rd quarter. Barclays PLC now owns 15,529 shares of the health services provider’s stock valued at $1,500,000 after purchasing an additional 5,142 shares during the period. HBW Advisory Services LLC purchased a new position in Amedisys during the 4th quarter valued at $38,000. Oak Thistle LLC increased its position in Amedisys by 97.6% during the 4th quarter. Oak Thistle LLC now owns 6,964 shares of the health services provider’s stock valued at $632,000 after purchasing an additional 3,440 shares during the period. Ballentine Partners LLC purchased a new position in Amedisys during the 4th quarter valued at $334,000. Finally, Nisa Investment Advisors LLC increased its position in Amedisys by 1.2% during the 4th quarter. Nisa Investment Advisors LLC now owns 15,150 shares of the health services provider’s stock valued at $1,375,000 after purchasing an additional 180 shares during the period. 94.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Stephens reaffirmed an “equal weight” rating and issued a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $100.00 target price on shares of Amedisys in a research report on Wednesday, April 16th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, Amedisys has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Stock Performance

Shares of Amedisys stock opened at $95.36 on Monday. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of 37.84, a PEG ratio of 1.78 and a beta of 0.96. The firm’s 50-day moving average is $92.97 and its 200 day moving average is $91.65. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.13 by $0.12. The company had revenue of $594.78 million for the quarter, compared to analysts’ expectations of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Amedisys’s revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.03 EPS. Sell-side analysts anticipate that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.